Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 15 of 15 for “"Immune Checkpoints"”.
-
Parp Inhibitor Upregulates Pd-L1 Expression and Enhances Cancer-Associated Immunosuppression
… antibodies that block CTLA4, PD-1 and PD-L1, immune checkpoints have emerged as new targets in cancer therapy. In addition, there is accumulating evidence highlighting the role of cancer-associated immunity in patient response to cytotoxic anticancer agents. Inhibitors of poly (ADP-ribose) …
-
Understanding and Targeting The Immunosuppressive Tumor Microenvironment
<p>Immune checkpoint inhibitors (ICIs), such as anti-PD1/PD-L1 and anti-CTLA-4, have shown impressive antitumor efficacy by improving the activity of T cells. While these inhibitors work in many patients with various cancer types, they have minimal or no effect in many more patients. Mounting …
-
T Cell Exhaustion in Glioblastoma
… treatment strategies such as immunotherapy. Immune checkpoint blockade is a type of immunotherapy which seeks to perpetuate T cell activity by blocking inhibitory immune checkpoints. This strategy has gained FDA approval in several solid tumors, yet has failed in GBM. Severe T cell …
-
Development of 89Zirconium-PET Tracers for Immune Cell Imaging
… of conditions such as genetic diseases, autoimmune disorders and cancer. The emergence of genetically engineered T cells expressing chimeric antigen receptors (CAR T-cells), together with modulations of immune checkpoints have brought the rapidly advancing field of immunotherapy into a new, …
-
Étude de l’expression et du rôle du ligand du co-stimulateur inductible des cellules T (ICOSL) dans les ostéoclastes humains
… in the bone microenvironment with bone cells and immune cells present in the adjacent bone marrow. Osteoclasts, which degrade the bone matrix, express costimulatory molecules on their surface, like antigen-presenting cells, which enable them to interact with immune and cancer cells, exerting an …
-
Glioblastoma: multifaceted immunosuppression mediated through galectin family members
… describe the distribution of intratumoural immune cells, and characterise the effects of secreted immunomodulatory on adaptive immune effector cells. Mass spectrometry data identified galectin family members in the glioblastoma secretome. ELISA assays confirmed galectin presence in …
-
Functional Genomic Studies of Cancer Immune Evasion Using In Vitro and In Vivo CRISPR/Cas9 Genetic Screens
… have shed light on the mechanisms of cancer immune evasion. An accumulation of data in recent years has identified several immune checkpoints, whose expression by cancer cells allows them to evade anti-cancer immune responses. The great potential of these findings is highlighted by the recent …
-
Molecular Mechanisms of Lymphocyte Activation - Please Mind the Gap
… gap between an antigen-presenting cell and an immune cell excludes large, inhibitory phosphatases, causing cell signalling. This work examines lymphocyte signalling phenomena in the light of the KS model. Single molecule and bulk experiments explore how the gap size between immune cells and a …
-
Bhlhe40: Required For Tumor Microenvironment Remodeling and Immune Checkpoint Therapy Efficacy
… Hodi et al., 2010). Immunotherapy, specifically immune checkpoint therapy (ICT) provides antagonist effect on specific immune checkpoints to control effector T cell functions(Pardoll, 2012). This therapy allows for the modulation of anti-tumor responses through the use of monoclonal antibodies, …
-
P4HB TARGETING HALTS TUMOR GROWTH AND RE-SENSITIZES RESISTANT MELANOMA CELLS TO DABRAFENIB AND TRAMETINIB STANDARD-OF-CARE THERAPY VIA IRE1-⍺ ACTIVATION AND AKT DOWNMODULATION
… targeted therapy (BRAF and MEK inhibitors) and immune checkpoints inhibitors (anti-PD1, anti-CTLA4). However, a significant proportion of BRAF-mutant patients develop secondary resistance to targeted therapies, while others exhibit even primary resistance. To either prevent or overcome …
-
TRANSLATIONAL RESEARCH TARGETING BILIARY TRACT CANCER
… treatment against CCA, the exploration of the immune background of GBC, and the establishment of a CCA mouse model mimicking mutation profiles of CCA patients.</p> <p>Patients with cholangiocarcinoma have poor clinical outcomes due to late diagnoses, poor prognoses, and limited treatment …
-
Delivery of sting agonist using lipid nanoparticles and discovery of anti-TIGIT peptides for cancer therapy
… mechanisms that cancer cells use to evade the immune system of their hosts in order to discover effective therapeutic interventions. Tumors can be classified based on their immunogenicity into two types: cold and hot tumors. Cold tumors like pancreatic cancer, glioblastoma, prostate cancer, and …
-
Clinical Relevance of the Immune Contexture and AXL Kinase in Triple-Negative Breast Cancer
… transition (EMT), and cancer-related immune responses. In particular, the tumour immune microenvironment and the interaction between immune and cancer cells are emerging as crucial factors in tumour progression, prognosis, and response to therapy in TNBC. In this study, we aimed to …
-
PROGRAMMED DEATH LIGAND 1 (PD-L1) IMMUNE CHECKPOINT-MEDIATED STIMULATION OF MALIGNANT PHENOTYPES IN TUMOUR CELLS
… Death 1 (PD-1)/Programmed Death Ligand 1 (PD-L1) immune checkpoint have focused on elucidating the signaling mechanisms leading to inactivation of immune effectors. We, along with others, have shown that signaling by the PD-1/PD-L1 immune checkpoint may be bidirectional. Hence, we hypothesized …
-
Elucidating The Roles of Il-15 In The Tumor Microenvironment
… IL-15 agonists in combination with anti-CTLA-4 immune checkpoint blockade synergistically induced better tumor growth control and enhanced mouse survival in a poorly infiltrated melanoma tumor model. These findings reveal the ability of IL-15 expressed within the TME to regulate TIL numbers and …